Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.35 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512967 | 1.00 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL19690438 | 0.87 | TDP1 (0.41) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL10065566 | 0.83 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL27415651 | 0.81 | SLC1A3 (0.34) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL5514482 | 0.81 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL25143817 | 0.81 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1TDP1SLC7A5 | |
| SCHEMBL20239746 | 0.81 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL16938119 | 0.80 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1TDP1ALDH1A1 | |
| SCHEMBL14679292 | 0.79 | ACE (0.40) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL380595 | 0.78 | SLC1A3 (0.35) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2696245-B1 | CONDUCTIVE MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC DEVICE | CANON KK (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-2450746-A1 | Positive resist composition and pattern forming method using the composition | Fujifilm Corporation (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2090627-B1 | Ink composition, ink set and image forming method | FUJIFILM CORP (JP) | 2011-08-10 | — | — | EP | disclosed |
| EP-1787964-A2 | Surface antifogging, antisoiling, tempered glass and method for producing the same | Fujifilm Corporation (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | SLC1A3 2431/4885SLC1A2 2468/4885SLC1A1 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.